Insider Selling: Twist Bioscience (NASDAQ:TWST) SVP Sells $25,410.12 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 291 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $87.32, for a total value of $25,410.12. Following the transaction, the senior vice president directly owned 120,414 shares of the company’s stock, valued at approximately $10,514,550.48. This represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Up 7.5%

TWST stock traded up $6.35 during trading on Wednesday, hitting $91.35. 2,440,610 shares of the company’s stock were exchanged, compared to its average volume of 1,477,205. The business has a 50-day moving average price of $64.56 and a two-hundred day moving average price of $50.23. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $5.69 billion, a price-to-earnings ratio of -68.68 and a beta of 2.23. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $93.80.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, May 4th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The company had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. During the same quarter in the prior year, the company earned ($0.66) earnings per share. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.02 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on TWST. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Robert W. Baird upped their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Barclays increased their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday. Leerink Partners set a $80.00 price objective on Twist Bioscience in a research report on Friday, May 22nd. Finally, Guggenheim lifted their target price on Twist Bioscience from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $74.60.

Institutional Trading of Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its holdings in Twist Bioscience by 11.8% in the first quarter. Royal Bank of Canada now owns 40,373 shares of the company’s stock valued at $1,585,000 after buying an additional 4,254 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Twist Bioscience by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,310 shares of the company’s stock worth $2,765,000 after acquiring an additional 3,181 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Twist Bioscience by 4.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 932,978 shares of the company’s stock worth $36,629,000 after acquiring an additional 37,577 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Twist Bioscience by 18.9% in the 1st quarter. Intech Investment Management LLC now owns 28,917 shares of the company’s stock worth $1,135,000 after acquiring an additional 4,591 shares during the period. Finally, Norges Bank acquired a new stake in shares of Twist Bioscience in the 2nd quarter worth approximately $737,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.